三生制药今日盘中大涨5.10%，引起了市场的广泛关注。
消息面上，美国临床肿瘤学会（ASCO）年会于今日正式开幕，三生制药的核心在研管线PD-1/VEGF双特异性抗体SSGJ-707的两项临床研究入选大会，其中一项获得了快速口头报告资格。已公布的数据显示，SSGJ-707在单药治疗晚期非小细胞肺癌的II期研究中，确认的客观缓解率（ORR）达到67.6%，中位无进展生存期（PFS）为12.4个月；在联合化疗一线治疗子宫内膜癌的II期研究中，确认的ORR分别高达85.7%和80.0%。这些积极的临床试验数据显著增强了市场对公司该产品未来前景的信心。此外，该产品此前已由辉瑞公司获得海外权益，总交易额超过60亿美元，这进一步验证了其商业价值。
与此同时，今日生物科技板块整体表现强势，板块内的共振效应也为三生制药的股价上涨提供了额外的助力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.